The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

Powdered composition comprising: (a) 100 parts by weight of at least one polyhydroxyalkanoate (PHA) in the form of particles having an average diameter (d50) from 1 μm to 100 μm, preferably from 5 μm to 60 μm; (b) from 0.1 to 10 parts by weight, preferably from 0.5 to 5 parts by weight, of at least one silicate or silica. The powdered composition, having a relatively low abrasivity index and high flowability, can be used in air-polishing without causing excessive abrasion of the enamel and of the root cementum and without causing sticking in the device. Furthermore, the presence of PHA, being a polymer characterized by high biodegradability, makes the powdered composition particularly suitable for use in the oral cavity.

The present disclosure relates to an oxygen-permeable topically-applied composition (OPTC) and methods of its use for the treatment of skin conditions and injuries.

The present disclosure relates to an oxygen-permeable topically-applied composition (OPTC) and methods of its use for the treatment of skin conditions and injuries.

The present disclosure relates to an oxygen-permeable topically-applied composition (OPTC) and methods of its use for the treatment of skin conditions and injuries.

The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.

The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.

The present disclosure relates to an oxygen-permeable topically-applied composition (OPTC) and methods of its use for the treatment of skin conditions and injuries.

The present disclosure relates to an oxygen-permeable topically-applied composition (OPTC) and methods of its use for the treatment of skin conditions and injuries.